Beishangs fund had a floating profit of 281.6 billion yuan in the year, and had a heavy position in science and technology medicine stocks

 Beishangs fund had a floating profit of 281.6 billion yuan in the year, and had a heavy position in science and technology medicine stocks

Since the opening of interconnection, Beishang capital has never stopped the pace of buying, buying and buying, with a total net purchase of 1.14 trillion yuan, including 148.46 billion yuan since this year, and more than 30 billion yuan in only two trading days since July. From the situation in the first half of the year, affected by the epidemic, the A-share market is facing a decline, while some industry sectors also ushered in certain investment opportunities.

According to data bank statistics, in terms of a single trading day, the average daily net purchase amount in 2020 will exceed 1.3 billion yuan, second only to the level in 2019. Further statistics show that since the opening of interconnection, the net purchase amount has exceeded 10 billion yuan in 16 trading days, and more than half of them will appear in 2020. On June 19, this year, the net purchase volume reached the second highest in history, exceeding 18 billion yuan; on February 3, this year, the net purchase amount of northbound capital reached 18.19 billion yuan, the third highest in history.

Since Beishang capital entered the A-share market, its investment style has always been in favor of large finance and large consumption, which are relatively stable and have long-term investment value. Since the rapid rise of 5g since last year, science and technology stocks have become the main line throughout the A-share market, and funds from all walks of life have increased their positions in science and technology stocks. Since this year, affected by the epidemic situation, the performance of medicine stocks related to the epidemic situation has also ushered in explosive growth.

Compared with the past, there are also some changes in the position of Beishang capital. Taking the annual as the statistical interval (up to July 3, 2020), according to the change range of the number of shares held by various industries, compared with the end of 2019, the top three capital positions of Beishang in 2020 were commercial trade, computing machine and medical biology, with the increase rates of more than 35%. It is not difficult to find that the large increase of positions in these three industries is due to the epidemic situation and the sustained strength of science and technology stocks.

According to the data of 2019, compared with the end of 2018, the computer warehouse increase rate is the first; the commercial trade and pharmaceutical biological warehouse increase rate ranks the 15th and 18th in the industry; the light industry manufacturing and non-ferrous metal industry rank the second and third.

Traditional industries such as comprehensive, mining and construction materials will be reduced in 2020, but the increase of positions in the above three industries will be in the forefront of the industry in 2019.

Heavy positions in technology and pharmaceutical stocks in the first half of the year

Beishang capital has always been guided by the style of value investment. It is good at selecting leading performance stocks in the industry as key investment objects. The proportion of its shares in the circulating shares is very high. During the year, the proportion of foreign shares in several stocks, such as Sophia, Midea Group, Sinochem, tiger pharmaceutical, and Guanglianda, has exceeded the warning line.

In terms of style, last years Beishang capitals heavy positions were mainly consumer and household appliance stocks. In the first half of this year, in addition to consumer stocks, individual stocks of science and technology and pharmaceutical industries were also favored. Compared with last year, the number of science and technology stocks and pharmaceutical stocks accounted for a large proportion of the newly added individual stocks with a shareholding ratio of more than 10%. In particular, this year, Huawei, apple, Tesla and other popular concepts have taken turns, making the technology market hot A-share, and some stocks in the science and technology industry chain have also become heavy positions of Beishang capital.

Up to the latest, 35 shares of Beishang capital held more than 10%, and Shanghai airport, Sofia, Weil shares were more than 20%. Mobile telecom, which is also a hot concept such as Huawei, 5g and chip, has become the biggest stock affected by foreign investors this year, with the number of shares increased by 106 times.

The amount of floating profit in the year reached 281.6 billion

As a representative of smart capital, what is the profitability of Beishang capital in a shares? According to the formula market value of shares held at the end of the period - (the value of stocks held at the beginning of the period + net purchases during the period) / (the value of stocks held at the beginning of the period + net purchases during the period), as of the latest closing date, the capital profit of Beishang was 18.5%, significantly better than that of the market. In terms of absolute profit, the market value of Beishang capital position was 18100, an increase of 430 billion yuan compared with 1.38 trillion yuan at the beginning of the year, and the net purchase amount of last year was 148.4 billion yuan. The floating profit of Beishang capital in the year reached 281.6 billion yuan.

If the time axis is extended, Beishang capital will make a profit of 42.43% in 2019 and 34.05% in 2017, both of which will significantly outperform the market; in 2018, Beishang capital will lose 19.56%, and the market will fall by 24.59%, still better than the market. It can be seen that northbound capital operation is more accurate as a whole.

Judging from the profit situation of individual stocks, the average increase since this year is 18.2%, far higher than that of the Shanghai index in the same period. Among them, 38 shares have increased by more than 50%. Since this year, UFIDA networks share price has increased by 111.75%, Chinas central immune system has increased by 105.45%, and lens technology has increased by 103.84%, ranking among the top three in the list of gainers. Among them, Beishang capital had a heavy position in Chinas CMAC at the beginning of the year, which amounted to 20 billion yuan, which was hyped by the concept of tax exemption. The large cap stocks with a market value of 300 billion yuan rose continuously and the share price doubled in the year.

As of the latest data, the shareholding market value of Beishang capital has reached 1.8 trillion yuan, accounting for 3.34% of the total circulating market value of A-shares, only 2.96% in 2019 and 1.9% in 2018. The voice of Beishang capital in A-share continues to improve, and many of the top ten circulating shareholders of the shares appear in the list of land shares.

Beishang capital flow is highly related to the rise and fall of the Shanghai index. When Beishang capital is bought in a large amount, the market is more likely to rise, and when it is sold sharply, the market is more likely to go down.

In addition, Beishang capital has a more sensitive sense of smell, and performs well in controlling risks and seizing opportunities.

In June, the PMI of Chinas official manufacturing and non manufacturing industries increased by 0.3 and 0.8 percentage points respectively compared with the previous month, confirming that the economic operation has been accelerating since March and slowly getting rid of the impact of the epidemic. Previously, most foreign-funded institutions believed that Chinas economy would lead the world this year, but they still underestimated the strength of Chinas economic rebound. The accelerated inflow of capital to the North fully shows the attitude of foreign capital. The rise of a shares is inseparable from the assistance of Beishang capital. Beishang capital bought 30.309 billion yuan in the two trading days of July 2 and July 3. Among them, Shanghai Stock connect bought 19.202 billion yuan and Shenzhen Stock connect bought 11.107 billion yuan.

A total of 26 stocks were listed on the list of active transactions this month. The largest amount of transaction was Maotai, Guizhou, with a total turnover of 6.175 billion yuan this month; Wuliangye was followed by a total of 4.306 billion yuan; China Ping An and China immune Insurance Co., Ltd. were also higher in transaction amount.

According to the statistics of net trading amount, there are 18 stocks on the list this month. Luzhou Laojiao had the largest net purchase amount, with a net purchase amount of 1.197 billion yuan this month, followed by Sany Heavy Industry and Guizhou Maotai, with net purchase amount of 938 million yuan and 912 million yuan respectively. Among the net selling stocks, BOE a, the panel leader, has the largest net sales, with a net sales volume of 837 million yuan this month.

In this month, there were 1017 stocks with a total of 1017, and 72 stocks with a margin of over 0.5 percentage point. Specifically, the proportion of eight party shares increased significantly, with the latest shareholding ratio of 9.23%, increasing by 2.6 percentage points on a month on month basis; followed by Dali technology, which increased by 1.83 percentage points month on month; the other top positions were Netshop technology, fengyuzhu, Jidan biology, etc.

From the perspective of market performance, the top 20 stocks of Beishang capital increased more than decreased this month, 17 stocks rose and 2 stocks fell. Ziguang Guoweis share price rose the most this month, up 33.1%; Boya bio rose 21.47%; other big gains were Huamao logistics, Hongta securities, Yunnan germanium industry, etc.

Beishang capital has bought 27 shares for 7 consecutive weeks. Statistics show that Beishang capital has bought 120 shares for 4 consecutive weeks. In terms of industry, there are 18 stocks in the pharmaceutical and biological industry. To lengthen the time, 27 shares were added by Beishang capital for 7 consecutive weeks. From the change of shareholding ratio, Sofia gained the largest increase in its position, which increased by 5.93 percentage points compared with that seven weeks ago; FAW Jiefang, QIMINGXING star, Guiyan platinum industry and Xinao Co., Ltd. also had more positions. From the perspective of market performance, among the seven consecutive weeks of Beishang capital, 24 stocks rose last week, among which FAW Jiefang gained the most, up 12.93%. Other big gainers were Huada gene, Desai Xiwei and Oceanwide holdings. Jinyu medicine and so on have a larger decline. Source: Securities Times editor in charge: Yang Bin_ NF4368

From the perspective of market performance, among the seven consecutive weeks of Beishang capital, 24 stocks rose last week, among which FAW Jiefang gained the most, up 12.93%. Other big gainers were Huada gene, Desai Xiwei and Oceanwide holdings. Jinyu medicine and so on have a larger decline.